What are you searching for?

01.12.2021 | Tracker

Product Launch Tracker: HCPs welcome approvals for MSD’s Keytruda and Takeda’s Livtencity

CREATION Team photo of Research Associate Paul Cranston CREATION Team photo of Health Stratge Associate Tomi Shobande By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout November 2021 we tracked the global conversations of 3,037 HCPs who posted 4,615 English-language Twitter posts about the launches and approvals of new products.

Image of a graph showing HCP mentions of product launches on twitter in November 2021

Over the course of November, the FDA approval of Merck MSD’s Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma (RCC) was the key talking point among HCPs. The treatment is to be used in patients at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. HCPs were pleased with the news as they saw it as a step in the right direction and a game-changer for the kidney cancer therapy area.

The FDA also approved Takeda’s Livtencity (maribavir) as the first and only treatment for people aged 12 and older with post-transplant cytomegalovirus (CMV) that is refractory, with or without genotypic resistance, to conventional antiviral therapies. HCPs shared their excitement for the approval of Livtencity (maribavir) and look forward to more treatment options being available.

HCPs also welcomed the news that the European Medicines Agency (EMA) recommended Pfizer’s COVID-19 Vaccine for approval in children aged 5-11. This age group would receive a lower dose of the Comirnaty vaccine than used in people aged 12 and older.

The three most shared links from HCPs discussing product launches in November were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • Using CREATION Pinpoint®, the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 November and 30 November 2021 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 November and 30 November 2021, there were 4,615 HCP mentions of new pharmaceutical product launches and drug approvals from 3,037 unique HCP authors from around the world. 

View the latest product launch and archived trackers here

View all articles >

CREATION Team photo of Research Associate Paul Cranston

Meet the Authors

Paul Cranston

Suggested next


A CREATION Press Release

15.01.2013 | Press Release

Creation Pinpoint® Provides Window on Doctors’ Online Conversations

Creation Healthcare today launches Creation Pinpoint®

HCPs quick to forgive Celgene’s advert

20.06.2019 | Article

HCPs quick to forgive Celgene’s advert

During the European Haematology Association 2019 Congress, Celgene released what healthcare

By Mary Kangley

View all articles >